SCHEMBL882180

SCHEMBL882180

C1=CC2=Nc3ccccc3SC2=CC1

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.36
DRD2 P14416 1/20 0.33
BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929279 0.78
SCHEMBL15000925 0.78 ALDH1A1 (0.35)
SCHEMBL14456136 0.75 HDAC8 (0.33)
SCHEMBL15000927 0.73 KDM4E (0.31) BACE1
SCHEMBL21835118 0.72 TRPA1 (0.35) TRPA1DRD2BACE1
SCHEMBL6528281 0.71 GPR84 (0.33) TRPA1
SCHEMBL29450353 0.71 GPR84 (0.33) TRPA1
SCHEMBL28461077 0.70 BACE1 (0.33) TRPA1DRD2BACE1
SCHEMBL407792 0.70 DRD2 (0.33) TRPA1DRD2BACE1
SCHEMBL9461527 0.69 PPARA (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383624-B2 Cargo delivery system and composition comprising the same SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-12 US claimed
US-11851685-B2 Zwitterion buffer containing compositions and uses in electroanalytical devices and methods ROCHE DIABETES CARE, INC. (US) 2023-12-26 US claimed
CN-118307571-A 2, 6-Modified boron fluoride fluorescent molecule and preparation method and application thereof 无锡学院 2024-07-09 CN disclosed
WO-2024050513-A1 PHENOTHIAZINES FOR TREATING MITOCHONDRIAL DISEASE ACUREX BIOSCIENCES CORPORATION (US) 2024-03-07 WO disclosed
US-11851685-B2 Zwitterion buffer containing compositions and uses in electroanalytical devices and methods ROCHE DIABETES CARE, INC. (US) 2023-12-26 US disclosed
CN-115210219-A Oxime ester photoinitiators 巴斯夫欧洲公司 2022-10-18 CN disclosed
US-20220275348-A1 ZWITTERION BUFFER CONTAINING COMPOSITIONS AND USES IN ELECTROANALYTICAL DEVICES AND METHODS ROCHE DIABETES CARE, INC. 2022-09-01 US disclosed
US-11377415-B2 Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2022-07-05 US disclosed
EP-3760607-A1 METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST Takasago International Corporation (JP) 2021-01-06 EP disclosed
US-20200399200-A1 METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST TAKASAGO INTERNATIONAL CORPORATION (JP) 2020-12-24 US disclosed
CN-110343100-B Phenothiazine co-sensitizer and preparation method and application thereof 江苏理工学院 2020-10-30 CN disclosed
WO-2012040599-A1 RADICALLY POLYMERIZABLE PHENOTHIAZINE MACROMONOMER FOR USE IN THE COATING OF MEDICAL DEVICES BAYER HEALTHCARE LLC (US) 2012-03-29 WO disclosed
CN-102369615-A Organic electroluminescent element and material for organic electroluminescent element IDEMITSU KOSAN CO 2012-03-07 CN disclosed
CN-102334210-A Organic electroluminescent element IDEMITSU KOSAN CO 2012-01-25 CN disclosed
US-20110253944-A1 NOVEL ORGANIC SEMICONDUCTOR COMPOUND, METHOD FOR PREPARING SAME, AND ORGANIC SEMICONDUCTOR COMPOSITION, AND ORGANIC SEMICONDUCTOR THIN FILM AND ELEMENT CONTAINING THE SAME LUMINANO CO., LTD. (KR) 2011-10-20 US disclosed
CN-101925851-A Liquid-crystal alignment material and liquid-crystal display element NISSAN CHEMICAL IND LTD 2010-12-22 CN disclosed
CN-101925850-A Liquid-crystal alignment material, liquid-crystal alignment film, and liquid-crystal display element NISSAN CHEMICAL IND LTD 2010-12-22 CN disclosed
CN-1202800-A Herbicidal composition NOVARTIS AG (CH) 1998-12-23 CN disclosed
CN-1144526-A Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents NISSAN CHEMICAL IND LTD (JP) 1997-03-05 CN disclosed
EP-0155623-A2 Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition MERCK & CO. INC. (US) 1985-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377415-B2 Method for converting N,N-dialkylamide compound into ester compound using complex of fourth-period transition metal as catalyst NEK4, TENT4A, TCF4 TRPA1 2148/4885DRD2 2975/4885BACE1 1379/4885
US-12383624-B2 Cargo delivery system and composition comprising the same ATG7, SQSTM1, BECN1 TRPA1 4401/4885DRD2 4330/4885BACE1 2525/4885
US-20110253944-A1 NOVEL ORGANIC SEMICONDUCTOR COMPOUND, METHOD FOR PREPARING SAME, AND ORGANIC SEMICONDUCTOR COMPOSITION, AND ORGANIC SEMICONDUCTOR THIN FILM AND ELEMENT CONTAINING THE SAME TYR, FTO, PIEZO1 TRPA1 40/4885DRD2 1830/4885BACE1 1419/4885
US-20200399200-A1 METHOD FOR CONVERTING N,N-DIALKYLAMIDE COMPOUND INTO ESTER COMPOUND USING COMPLEX OF FOURTH-PERIOD TRANSITION METAL AS CATALYST NEK4, TENT4A, TCF4 TRPA1 2148/4885DRD2 2975/4885BACE1 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.